

Cyxone and Medical University of Vienna announce collaboration to study broader T20K use in MS

After identifying some valuable new potential treatments for T20K, Cyxone AB (publ) (“Cyxone or the Company”) today announced that the company has entered into a research collaboration with Prof. Christian Gruber, the inventor of T20K & Prof. Gernot Schabbauer from the Medical University of Vienna. The aim of the study is to deepen the understanding of the mode of action (MoA) of T20K and to explore these new uses and the potential to provide significant additional therapeutic benefit in a model for multiple sclerosis. The study will start later this month, with planned readout in June 2022, and constitutes studies required for approval to test in humans with the new administration form.

T20K is a potential first-in-class peptide drug candidate that shows promise as a novel and safe therapy which can halt the progression of MS. T20K has been shown to both delay disease development and to halt its progression once disease has been initiated in animal models, thereby positioning T20K as a therapy for early intervention in MS which could potentially improve the quality of life for MS patients by delaying or even stopping the diseases progression. The collaboration with Med Uni Vienna will explore if there is a therapeutic effect which can be beneficial for other MS patient subsets. The project is part of the ongoing preclinical development activities for T20K, and the studies are important to be able to apply for approval to go into clinical phase 1.

“I am very pleased that Cyxone has chosen our lab for its studies” said Prof. Gernot Schabbauer, “I will work in close collaboration with Christian Gruber, the inventor of T20K and Cyxone, and I have a keen interest in studying the immune effect and therapeutic effect of this potentially powerful new therapeutic candidate in our novel experimental design.”

The aim is also to confirm the results from previously performed studies with T20K in an *in vivo* model. A new study design will be applied in this collaboration with the purpose of gaining more in-depth knowledge of the MoA and to deepen the scientific understanding of how T20K works in the body. New possibilities for the treatment will also be tested to determine if there is broader potential for T20K.

"By building collaborative scientific relationships around the world, like this alliance, we are crafting an environment where new scientific perspectives may help to validate and develop T20K towards a life-changing treatment for the benefit of patients. We are becoming a more science driven company and this will open up more possibilities. With a successful outcome, we will potentially also be able to expand the therapeutic scope of T20K in MS and potentially beyond MS. Cyxone intends to exploit the full therapeutic potential and full value of T20K for patients and for our shareholders.", says Tara Heitner, CEO of Cyxone AB.

Contact

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

Forward-looking statements

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com

About Medical University of Vienna

Medical University of Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training centre in the German-speaking countries. With 5,500 employees, 30 departments and two clinical institutes, 12 medical theory centres and numerous highly specialised laboratories, it is also one of Europe's leading research establishments in the biomedical sector.